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ARA 290Many disease processes activate a cellular stress response that initiates a cascade of inﬂammation and damage.
However, this process also triggers a tissue protection and repair system mediated by locally-produced
hyposialated erythropoietin (hsEPO). Although recombinant EPO is used widely for treating anemia, potential
use of recombinant EPO for tissue-protection is limited by rises in hematocrit, platelet activation, and selectin
expression resulting in a high risk of thrombosis. Importantly, the erythropoietic and tissue-protective effects
of EPO are mediated by different receptors. Whereas EPO stimulates red cell progenitors by binding to an EPO
receptor (EPOR) homodimer, a heterodimer receptor complex composed of EPOR and β common receptor
(βcR) subunits, termed the innate repair receptor (IRR), activates tissue protection and repair. The IRR is
typically not expressed by normal tissues, but instead is rapidly induced by injury or inﬂammation.
Based on this understanding, EPO derivatives have been developed which selectively activate the IRR without
interacting with the EPOR homodimer. The latest generation of speciﬁc ligands of the IRR includes an 11
amino acid peptide modeled from the three dimensional structure of the EPO in the region of helix B called
pyroglutamate helix B surface peptide (pHBSP; ARA-290). Despite a short plasma half-life (~2 min), pHBSP
activates a molecular switch that triggers sustained biological effects that have been observed in a number of
experimental animal models of disease and in clinical trials. This review summarizes pharmacokinetic and
pharmacodynamic data and discusses the molecular mechanisms underlying the long-lasting effects of this
short-lived peptide.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Tissue damage or stress generally activates an evolutionarily ancient
inﬂammatory reaction that has been termed the innate immune
response. Central to this process is a self-amplifying production of
pro-inﬂammatory cytokines that cause further tissue damage through
necrosis and apoptosis via a positive feedback loop. Additionally, the
microenvironment becomes relatively hypoxic due to a disrupted
microcirculation coupled with increased metabolic activity of both
resident cells and inﬁltrating immune cells. This process is a prominent
component in a range of inﬂammatory disorders, such as chronic
infection, or inﬂammatory bowel disease (Taylor & Colgan, 2007; Werth
et al., 2010). Within this system, hypoxia- and inﬂammation-responsive
molecular pathways are closely inter-related and co-regulated
(Palazon et al., 2014). One critical molecular component of this
closely choreographed biological response is the family of hypoxia
inducible factor transcription factors (HIF) that activate a host of
metabolic pathways to restore cellular integrity (Semenza, 2012).
Tissue injury has been observed to cause an increase in HIF expression
(Bernaudin et al., 2002; Shein et al., 2005). Prominent among HIF-
regulated gene transcription is erythropoietin (EPO).
EPO is an evolutionarily ancient protein (Nogawa-Kosaka et al.,
2010) that can be synthesized by many cells. A major form of EPO is
as a hormone, a 31 kDa glycoprotein predominantly produced in the
adult kidney andprimarily known for its role in promotingproliferation,
differentiation and survival of erythroid progenitor cells (Watowich,
2011). It is clinically used for the treatment of patients with anemia
secondary to chronic kidney disease or myelodysplasia following
chemotherapy or radiotherapy.
When anemia develops, hypoxia is detected within the kidney
which stimulates the production and secretion of EPO which travels to
the bone marrow. There, EPO increases the production of erythrocytes
and therefore the circulating red cell mass, and in this manner, reduces
hypoxia. Within the setting of immune activation or tissue damage
throughout the body, however, the production of EPO acts as a master
regulator of apoptosis and pro-inﬂammatory cytokine production, as
well as of the repair of tissue damage.
2. Erythropoietin and its receptor isoforms
EPO produced by the kidney possesses 4 oligosaccharide chains
terminated by sialic acids that provide for a plasma half-life of 4–6 h.
In contrast, EPO that is produced locally as the result of innate immune
system activation is poorly sialated (Masuda et al., 1994), as would be
expected for a molecule operating in a paracrine/autocrine mode, and
therefore has a short half-life (Imai et al., 1990). Notably, completely
desialated EPO has a plasma half-life of approximately 1.4 min
(Erbayraktar et al., 2003). Hyposialated EPO (hsEPO) is believed to
be the ligand activating the innate repair system.
The EPO-receptor that mediates erythropoiesis is comprised of two
identical EPO receptor monomers (EPOR) which become localized
rapidly within the microdomains of the membrane rafts of hematopoi-
etic cells following stimulation (within severalminutes) (McGrawet al.,
2012). Here, the EPOR subunits spontaneously dimerize when in close
proximity, forming EPOR-EPOR [(EPOR)2] and assemble with Janus
kinase 2 (JAK2) andothermembers of themolecular signalingmachinery
(McGraw et al., 2012). Subsequently, when EPO binds to and bridges
across the receptor subunits, a conformation change occurs, leading to
activation of JAK2,which in turn phosphorylates tyrosine residueswithin
the EPOR cytosolic domain. The phosphorylation of (EPOR)2 results in the
activation of several signal transduction proteins, including themitogen-
activated protein kinase extracellular-regulated kinase (ERK)-1/2,
phosphatidyl inositol 3 kinase (PI3K)/Akt, and signal transducers and
activators of transcription (STAT)-5. STAT-5 that stimulatesmitochondrial
anti-apoptotic proteins, such as Bcl-XL, and consecutively inhibits cyto-
chrome c-dependent caspases, thus, suppressing erythroid progenitorcell apoptosis (Chong et al., 2002). Additionally, (EPOR)2 also mediates
platelet and endothelial cell activation, including up-regulation of
E-selectin (Heinisch et al., 2012). These actions serve to limit blood
loss following vascular trauma by activating physiologically relevant
thrombosis, but also serve to initiate and maintain inﬂammation.
One prominent characteristic of (EPOR)2 signaling pathways is that
activation consists of both binary (switching on) as well as graded
responses, for example, as in STAT-5 signaling (Porpiglia et al.,
2012).
EPO has a high afﬁnity (~200 pmol/L) for (EPOR)2, and as only a
few percent occupancy is needed for adequate signaling (Krzyzanski &
Wyska, 2008), the normal human serum EPO concentration is in the
1–10 pmol/L range. The endothelial cell was the ﬁrst non-hematopoietic
cell found to respond to EPO for which activation of the receptor causes
endothelial cell mitosis and migration. However, the effective concentra-
tions of EPO needed for this activity (1–2 nmol/L) were signiﬁcantly
higher than those required for hematopoiesis (Anagnostou et al., 1990).
Subsequently, the nervous system (Konishi et al., 1993), the kidney
(Westenfelder et al., 1999), and the heart (Calvillo et al., 2003) were
also shown to respond to EPO, but similar to endothelial cells, required
higher EPO concentrations than that needed for hematopoiesis. The
substantial difference between the afﬁnity of the (EPOR)2 expressed by
erythrocyte precursors and the one on non-hematopoietic cells suggested
that a different receptor might transduce tissue protection. Additionally,
the EPO receptor isolated from neuronal-like PC-12 cells was charac-
terized as having a different molecular weight and with distinctive
accessory proteins (Masuda et al., 1993).
Using a derivative of EPO with the binding sites to (EPOR)2
blocked, Leist and colleagues demonstrated that the erythropoietic
and cytoprotective effects of EPO could be separated (Leist et al.,
2004). Subsequent experimental data have provided good evidence
that the extra-hematopoietic effects of EPO are mediated, at least in
part, by an alternative receptor that is proposed to consist of a hetero-
complex between the EPOR and the β-common receptor (βcR; known
also as CD131) (Brines et al., 2004). βcR is a subunit also used for the
receptors of other type 1 cytokines, i.e., interleukin (IL)-3, IL-5 and
granulocyte-macrophage colony stimulating factor (Murphy & Young,
2006). We have named this alternative EPO receptor as the innate repair
receptor (IRR) to differentiate it from hematopoietic effects and to
emphasize its protective role in inﬂammation and tissue injury to reduce
damage, while also initiating healing and repair.
A distinct temporal-spatial relationship exists between components
of the innate immune response and initiation of tissue protection and
repair via IRR activation (Fig. 1). In quiescent cells, EPOR and βcR are
typically localized within the intracellular compartment and not
present on the cell surface. Stress, e.g. by hypoxia or inﬂammation,
induces a rapid (several minutes) movement to the cell surface (Bohr
et al., 2015) with a likely coalescence into membrane rafts, as has
been described for other heteroreceptors that utilize βcR (Saulle et al.,
2009), and as has been described above for the EPOR dimer (McGraw
et al., 2012). Assembly of the mature receptor would then allow for
stimulation if hsEPO is available in the surrounding locale. In this way,
the innate repair system acts as a complex lock and key system that
requires a speciﬁc time and spatial resolution to be present before
being activated.
As in the case of the dimeric erythropoietic receptor (EPOR)2 complex,
binding of EPO to the EPOR-βcR complex causes phosphorylation of JAK2.
This activation of JAK2 then switches on three principle signaling
cascades that depend upon the speciﬁc tissue examined: STAT-5,
PI3K/Akt, and mitogen-activated protein kinases (see below). These
signaling pathways induce regeneration, inhibit apoptosis and inhibit
inﬂammation (Brines & Cerami, 2008).
The binding afﬁnity of the classic (EPOR)2 complex is signiﬁcantly
greater than the binding afﬁnity of the tissue-protective EPOR-βcR
complex (Brines & Cerami, 2008). Thus, to induce local tissue protection,
considerably higher systemic doses of recombinant EPO (rEPO) are
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Fig. 1. The innate repair system is characterized by temporal and spatial separation of the innate repair receptor and its endogenous ligand, hyposialated EPO (hEPO). At baseline, the EPOR
and βcR subunits are maintained within the cell. Following cellular stress, e.g., hypoxia and inﬂammatory mediators, these receptor units are transported to the cell surface rapidly
(minutes) where spontaneous assembly occurs, probably within lipid raft micro-domains, forming the innate repair receptor. On the cell surface the βcR exists as an intertwined dimer.
After a signiﬁcant delay (hours in the case of central nervous system injury) hyposialated EPO is synthesized by cells in the vicinity of injury. If sufﬁcient ligand is present to diffuse into
the injury site, its binding to the innate repair receptor causes phosphorylation of JAK2, which then switches on signaling cascades leading to long lasting biological protective and reparative
responses are turned on. When the innate repair receptor is formed, exogenous selective ligands, e.g., pHBSP, can be administered to directly activate the tissue protective response.
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poiesis. As a result, the EPOR-βcR complex does not respond to EPO
at the 1–7 pmol/L concentrations normally present in the circulation
and is probably only activated by high levels of locally-produced EPO.
Additionally, as described above, the EPOR-βcR heterodimer is not
usually expressed until after an injury occurs, and only requires a brief
exposure to EPO to trigger sustained biological activity. This is in
contrast to the (EPOR)2 homodimer complex, which is normally
expressed in hematopoietic cells, and requires sustained levels of EPO
to support erythropoiesis.
A host of tissues and cells under stress have been shown to express
and co-localize EPOR and βcR, including the central (Brines et al.,
2004) and peripheral (Loesch et al., 2010) nervous systems, retina
(Colella et al., 2011), heart (Xu et al., 2009), kidney (Kitamura et al.,
2008), skeletal muscle (Collino et al., 2014), the endothelium
(Su et al., 2011), as well as macrophages and bone marrow derived
mesenchymal cells (Bohr et al., 2015).
3. Erythropoietin: an overview of its clinical potential beyond the
treatment of anemia
The potential therapeutic relevance of EPO in the clinical setting of
several diseases beyond the treatment of anemia, mainly in patients
with organ ischemic injury, has been recently investigated and shows
variable efﬁcacy (Patel et al., 2011a). The Gottingen EPO Stroke Study,
a pilot, double-blinded study, was the ﬁrst trial demonstrating that
EPO improves clinical outcome in patients with stroke as determined
1 month after the incident by neurological scoring and MRI (Ehrenreich
et al., 2002). However, the more recent German Multicenter EPO Stroke
Trial has unexpectedly documented that a combination of rEPO and
recombinant tissue plasminogen activator is not advantageous, and
may even be detrimental (Ehrenreich et al., 2009), as EPO also interacts
with the tissue metalloproteinases which are involved in tissue
remodeling (Zechariah et al., 2010). Clinical trials with low-dose
EPO in patients with myocardial infarction (MI) showed only minor
improvements of cardiac function (Ozawa et al., 2010; Taniguchi
et al., 2010; Voors et al., 2010), whereas a trial that used a higher
dose of EPO showed a tendency toward an increased incidence of
adverse events (Ott et al., 2010). Finally, a randomized, double
blind, placebo-controlled trial did not ﬁnd signiﬁcant reduction in
biomarkers of renal ‘injury’ in patients with acute kidney injury,which had been treated with EPO (Endre et al., 2010). However,
the biomarkers used in this trial are poorly validated to detect
acute kidney injury, and there were some differences in baseline
between placebo and EPO-treated patients, which make this study
difﬁcult to interpret.
EPO has also been reported to reduce the degree of insulin resistance
in patientswho have end-stage renal disease. In a case–control study on
59 age- and sex-matched patients with end-stage renal disease treated
by hemodialysis (stage 5), many of whom had diabetes, the mean plas-
ma insulin levels of hemodialysis patients treated with recombinant
human EPO were signiﬁcantly lower than in patients which had not
received EPO; and duration of EPO treatment negatively correlated
with insulin resistance (Khedr et al., 2009). This is in agreement with
other studies showing that hemodialysis patients treated with EPO are
more insulin sensitive when compared with hemodialysis patients not
treated with EPO (Spaia et al., 2000; Tuzcu et al., 2004).
Anypotential therapeutic application of EPO in patientswith chronic
diseases, includingmetabolic disorders, is limited by rises in hematocrit
and platelet count (hematopoietic effect), resulting in an increase in
thrombotic risk. For instance, in a large randomized, placebo-
controlled trial which enrolled 1460 critically ill patients (within
48 to 96 h of admission to medical and surgical ICUs) with EPO
(3 × 10,000 IU for a maximum of three weeks) resulted in a signiﬁcant
reduction in mortality in patients with trauma, but also in a signiﬁcant
increase in thrombovascular events (Corwin et al., 2007). The authors
speculate that the observed beneﬁcial effects of EPO are secondary to
the reported tissue-protective effects, while the adverse effects are due
to an activation of the ‘classical’ hematopoietic (EPOR)2. Additionally, a
large multicenter trial in traumatic brain injury recently has shown an
increase of adverse thrombotic events in the EPO treatment armwithout
clear beneﬁt on brain injury (Robertson et al., 2014). Thus, the develop-
ment of drugs that maintain the tissue-protective effects of EPOwithout
causing hematological complications may represent a signiﬁcant
advance in the treatment of several diseases, especially when the
interventions have to be administrated over weeks and months to
be effective.
Another concern of long-term administration of EPO is its potential
to promote tumor growth (Barbera & Thomas, 2010), which has
prompted regulatory agencies to issue warnings for the use of
erythropoiesis-stimulating agents in oncology patients, despite
reassuring recent ﬁndings reporting a lack of clinical evidence for
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et al., 2012). Notably, as the tumor progression by EPO is mediated
by the EPOR homodimer, drugs that selectively activate the innate
repair receptor are unlikely to exert this effect.
4. pHBSP: structure, pharmacodynamics and pharmacokinetics
Efforts have been made to design and validate EPO analogues with
speciﬁcity for the IRR (EPOR-βcR), enabling tissue-protective, but not
erythropoietic activity. These include either molecules based on the
modiﬁcation of the EPO protein (for example, asialo-erythropoietin,
obtained by enzymatic desialylation of EPO (Erbayraktar et al., 2003))
and carbamoylated EPO (Leist et al., 2004) (synthesized by cyanate
carbamoylation of EPO) and peptides that mimic the three-dimensional
structure of EPO (Brines et al., 2008). In general, modiﬁed proteins are
quite effective (Leist et al., 2004), but as potential pharmaceutical agents,
there are also the inherent problems of poor long-term stability,
antigenicity, as well as high costs of production. Here, we describe
the latest generation of a non-erythropoietic derivative mimicking
the spatial conﬁguration of EPO, pyroglutamate helix B surface peptide,
pHBSP, also known as ARA-290, illustrating the most recent ﬁndings
covering its tissue protective effects.
EPO is a globular protein due to the self-assembly of its 4 α-helices
A–D. Three of the helices (A, C and D) are hydrophobic and participate
in the two binding sites within the hematopoietic (EPOR)2, while the
remaining helix B, that is hydrophilic and points away from the EPOR,
appears to be involved in tissue-protection (Brines, 2010). It is notable
that helix B of EPO has been highly conserved in vertebrate evolution,
in spite of the fact it is not involved in binding to the homodimeric
EPOR underlying hematopoiesis (Brines & Cerami, 2013). Modeling
peptides on the 3-dimensional surface of helix B (surface simulation
modeling (Kazim & Atassi, 1980)) ultimately resulted in the generation
of a low molecular weight peptide, the Helix-B Surface Peptide (HBSP).
HBSP is an 11-amino acid, linear peptide that mimics the external,
aqueous face of helix B resembled EPO (including amino acids 58–85
of EPO that are exposed at the helix B surface as well as three residues
from the loop between helices B and C). The spontaneous cyclization
of the N-terminal glutamine gives rise to pyroglutamate HBSP
(pHBSP). The pharmaceutical product has pyroglutamate substituted
for the N-terminal glutamine, resulting in the amino acid sequence of
Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH (Pyr represents
pyroglutamic acid) and a molecular weight of 1258 Da. The N-
terminal substitution with pyroglutamate results in a peptide that is
stable for at least 2 years at 4 °C or up to 12 months at 25 °C. In vitro
testing has conﬁrmed that this small peptide derived from the binding
site of EPO to the EPOR-βcR complex binds the EPOR-βcR complex,
but not the erythropoietic (EPOR)2 homodimer (Brines & Cerami,
2008). In vivo tests have shown that it exerts the tissue-protective
activities representative of the full EPO molecule, without stimulating
hematopoiesis (Brines et al., 2008).
The pharmacokinetic behavior of pHBSP was determined after a
single i.v. dose to male Sprague–Dawley rats, receiving either
60 μg/kg (48 nmol/kg) or 180 μg/kg (143 nmol/kg) of pHBSP, and
to male New Zealand White rabbits, receiving either 30 μg/kg
(24 nmol/kg) or 90 μg/kg (72 nmol/kg) of pHBSP (Brines et al.,
2008). The mean peak drug concentration (Cmax) values were
254.67 (±53.59) and 1103.67 (±194.53) ng/ml for rats and 95.10
(±44.34) and 200.67 (±52.92) ng/ml for rabbits. Both Cmax and
area under the concentrations vs. time curve (area under the
curve) increased with increasing dose in a slightly more than dose-
proportional manner, although the variability between animals
within each dose group was considerable. The mean half-life was
0.028 h and 0.047 h for rats and 0.028 h and 0.038 h for rabbits.
More recently, a pharmacokinetic study on intravenous (i.v.) and
subcutaneous (s.c.) administration of pHBSP in healthy volunteers has
been performed, conﬁrming similar observations (Niesters et al.).Speciﬁcally, the results showed that 2, 4 and 6 mg s.c. of pHBSP caused
a dose-dependent increase in plasma Cmax from 1.8±1.4 ng/mL (2mg)
to 8.3 ± 4.0 ng/mL (6 mg) occurring at t = 12 and 15 min respectively
following injection with AUC of 53, 82, and 223 ng/mL/min, respectively.
The elimination half-life (t1/2 elim) estimation was ~20 min. In contrast,
2 mg i.v. caused a rapid peak in Cmax at min 1 of 111 ± 91 ng/mL with
a t1/2 elim of just 1.1 ± 0.1 min and AUC of 313 ng/mL/min.
5. Molecular mechanisms of tissue-protective effects
The rapid elimination after the i.v. injection is remarkable, suggesting
a rapid passage of the drug into the effect compartment and rapid
activation of the receptor followed by the initiation of a sustained
cascade of events involving a series of transduction factors. The under-
lying mechanisms of action of the reported beneﬁcial effects of pHBSP
are intriguing, as this peptide has a short plasmahalf-life, while the pro-
tective effects in animals and humans develop over hours to days. From
a pharmacokinetic/pharmacodynamics perspective, pHBSP behaves
similarly to a number of neuropeptides: sustained biological effects in
spite of very short biological half-lives. For example, adrenocorticotro-
pic hormone (ACTH) is a 39 amino acid peptide that is secreted from
the anterior pituitary in brief pulses with a biological half-life of only a
few minutes (Veldhuis et al., 1987). Tetracosactin (ACTH 1–24) is an
analogue which is used clinically to assess adrenal cortical function. In
a normal individual, an intravenous bolus of ACTH 1–24 disappears
from the circulation with a half-life of about 5 min and is eliminated
from the circulation rapidly, followed after a delay of 15–30 min later
with a sustained secretion of cortisol. Small versus large doses of
tetracosactin stimulate the same cortisol production rate, i.e., the
same peak level of cortisol and area under the curve (Alia et al., 2006).
Simultaneously, a single bolus of this peptide activates the prolonged
synthesis of enzymes involved in steroidogenesis (Lehoux et al., 1998).
As another example, teriparatide (1–34 parathyroid hormone)
has a half-life of only 5 min when given intravenously, yet switches
on receptor signaling (Castro et al., 2005) and stimulates long-
lasting effects on serum calcium concentrations, beginning about
2 h after dosing and declines to baseline by 16–24 h, long after the
peptide has been cleared completely from the circulation (Rubin &
Bilezikian, 2005). If given once daily subcutaneously, teriparatide
enhances bone formation. In contrast, more frequent or continuous
administration of teriparatide mimics hyperparathyroidism and
enhances bone resorption (Rubin & Bilezikian, 2005). Similar long-
lasting effects have been reported for the glucagon-like peptide-1
(GLP-1), which also has a very short biological half-life (1.5–5 min).
GLP-1 is a potent insulinotropic hormone, formed as a 30-amino acid
peptide secreted from the L-cells of the intestinal epithelium in
response to food. When GLP-1 is continuously infused to insulin
resistant animals, blood glucose is normalized (Sreenan et al.,
2000), with effects similar to those we recorded administering
pHBSP in our mouse model of diet-induced insulin resistance
(Collino et al., 2014). Notably, in an animal model of type 2 diabetes,
the GLP-1-dependent amelioration in glucose tolerance was still
detectable several days after the end of the infusion and the beneﬁcial
effect rather than declining, progressively increased, reaching a peak
at day 9 (Hui et al., 2002). Similarly, a single injection of the dipeptidyl
peptidase IV resistant analogue of GLP-1 (GLP-1-Gly8) in diabetic mice
corrected fasting hyperglycemia and glucose intolerance for several
hours, although this was in contrast to the rapid disappearance of the
peptide from the blood stream (Burcelin et al., 1999). Relaxin is another
peptide hormone, best known for the physiological role played during
pregnancy, which has shown promise in the treatment of diabetes,
heart failure, neurodegenerative diseases, hypertension, dyspnea and
wound healing, despite its short serum half-life (1–3 min) (Cernaro
et al., 2014). We have recently demonstrated that the beneﬁcial effects
of acute relaxin administration against renal ischemia/reperfusion (I/R)
injury were still detectable 3 h after its last administration and they
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for pHBSP, including Akt-dependent endothelial nitric oxide·synthase
(eNOS) activation (Collino et al., 2013). Overall, the above studies
support the view that the pharmacodynamic effects of small peptides
may actually bemuch longer than anticipated by their pharmacokinetic
half-life.
In a similar manner to agents described above, pHBSP produces a
uniform response once a Cmax is obtained that is N1 nmoles/L. For
example, in a kidney I/R model a 10-fold increase in pHBSP dose
produces the same biological effect (Brines et al., 2008). The protective
effects were time-dependent, as administration of pHBSP signiﬁcantly
attenuated the I/R induced rise in plasma parameters of kidney function
only when administered at 6 h. In contrast, early administration of
pHBSP at either 1 min or 30 min into reperfusion had no signiﬁcant
effect when compared to vehicle control mice. In the same model, a
single dose administered with a 6 h delay produces sustained effects
when evaluated 48 h later as shown by an increase in Akt phosphor-
ylation, associated with an enhanced eNOS activation, thus resulting
in protection against renal I/R injury (Patel et al., 2012).
As recently conﬁrmed in different cell lines of mesenchymal origin,
the beneﬁcial effects of pHBSP in restoring tissue homeostasis aremainly
due to selective modulation of apoptotic and inﬂammatory pathways
secondary to the activation of the heteromeric EPOR-βcR complex that
is rapidly recruited to the cell surface following cellular stresshEPO
JAK2
Fig. 2.Multiple intracellular signaling pathways are implicated in the biological activity of pHB
phosphorylation and activation of janus kinase-2 (JAK2). Subsequently, signal transducers and tran
systems are variably activated depending upon the tissue. Downstream sustained activation in sur
Redrawn from ref (Brines & Cerami, 2012.(Bohr et al., 2015). Speciﬁcally, pHBSP was able to overcome a
TNFα-mediated inhibition of transcription factors activation related
to cell stress responses, such as the heat shock transcription factor
protein-1 and the activator protein-1, thus affecting the transcriptional
activation of various nuclear promoter sites related to cell stress
responses and cell cycle control. All of these transcriptional responses
are sustained and persist beyond exposure of the cells to pHBSP.
Below we outline the most interesting signaling pathways involved in
pHBSP mechanism of action (Fig. 2), which could help to explain, at
least in part, its long-lasting beneﬁcial effects.
Much experimental evidence suggest that the anti-inﬂammatory
and anti-apoptotic effects associated with the activation of EPOR-βcR
are due, at least in part, to the phosphorylation of Akt. In cultured
neonatal rat cardiomyocytes and in the cardiomyopathic hamster,
pHBSP activated Akt in a dose dependent manner reaching a maximum
with a concentration of 2 nmoles/L. This effect was associated with
signiﬁcant inhibition of the apoptosis induced by TNF-α. In the same
experimentalmodels, pHBSP caused activation of other critical signaling
pathways of cell survival, including ERK1/2, and STAT-3 (Ueba et al.,
2010). Using a small interfering RNA approach, the authors conﬁrmed
that among the several pathways activated by pHBSP, only Akt plays
an essential role in the prevention of apoptosis afforded by pHBSP.
Similarly, silencing of theβcR abolished the Akt phosphorylation caused
by EPO in endothelial colony-forming cells (Bennis et al., 2012).pHBSP
JAK2 P
SP. pHBSP or hyposialated EPO interacts with the innate repair receptor initially causing
scription factors, including STAT, Akt, AMPK, NF-kB and themitogen-activated protein kinase
vival, tissue reparative, and anti-inﬂammatory pathways leads to tissue protection and repair.
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effect of pHBSP in a murine model of renal I/R injury (Yang et al., 2013).
The PI3K/Akt axis is also known to regulate phosphorylation of the
eNOS on Ser1177 in conjunction with the ERK1/2 signaling pathway.
NOS activity is a physiologic regulator of cardiovascular function and
physiological angiogenesis. Increased phosphorylation of eNOS causes
activation of eNOS and results in an enhanced formation of NO in the
microcirculation, which may contribute to the observed protective
effects of EPO. The reduction of renal injury/dysfunction caused by
pHBSP in a porcine model of I/R injury in the pig was associated with
increased urinary nitrite + nitrate concentrations, suggesting increased
eNOS activity (van Rijt et al., 2013). The phosphorylation (activation) of
both Akt and eNOS afforded by EPO in the heart (Khan et al., 2013) and
kidney (Coldewey et al., 2013) of septic mice is also silenced in βcR
knockout mice, indicating that activation of the IRR by EPO is essential
for the observed beneﬁcial effects. Overall, these results indicate that
the activation of the Akt/eNOS pathway plays a pivotal part in the
observed beneﬁcial effects of pHBSP.
In addition to causing an activation of eNOS secondary to activation
of the PI3K/Akt pathway, EPO has been observed to also increase eNOS
phosphorylation by enhancing the activity of AMP-activated protein
kinase (AMPK) activity. This regulator of energymetabolism is integrat-
ed in EPO signaling via the βcR and inhibition of AMPK reduces eNOS
phosphorylation (Su et al., 2011). In addition, an interaction between
the βcR and the vascular endothelial growth factor receptor-2 has
been described as being necessary for an activation of eNOS by EPO
(Sautina et al., 2010). However, the signal transduction elements that
link activation of the βcR by pHBSP to the vascular endothelial growth
factor receptor-2 are not understood at present.
The PI3K/Akt signaling pathway is one of the most important path-
ways for cell survival and its activation by pHBSP via heterodimeric
EPOR-βcR complex ameliorates apoptosis in models of renal I/R injury
(Yang et al., 2013) and critical limb ischemia (Joshi et al., 2014). This
is consistent with another study demonstrating that a peptide similar
to pHBSP decreased apoptosis in response to renal I/R injury, via induc-
tion of the anti-apoptotic molecule Bcl-2 (Chattong et al., 2013).
The PI3K/Akt pathway plays also an important role in glucose
metabolism and insulin signaling. Insulin receptor signaling through
Akt promotes translocation of the glucose transporter type 4 by acti-
vation of AS160, resulting in increased glucose uptake. We recently
demonstrated that pHBSP attenuated the impairment in insulin
signaling, caused by a high fat, high sucrose (HFHS) diet in skeletal
muscle (Collino et al., 2014). Speciﬁcally, pHBSP counteracted the
HFHS-induced alterations in the phosphorylation of key insulin
signaling molecules, Akt and its downstream substrate glycogen
synthase kinase-3β. These effects were accompanied by a signiﬁcant
increase in the phosphorylation of AS160, followed by a marked
improvement in membrane translocation of the glucose transporter
type 4 and a robust increase in muscle glycogen content.
Finally, pHBSP has also been reported to alter T cell polarization
and differentiation, but not proliferation (Chen et al., 2014; Cravedi
et al., 2014). However, the exact mechanism of pHBSP-derived
immunomodulation remains uncertain. An immune modulation in
response to pHBSP was observed in a model of Escherichia coli invasion
into urothelial cells, by reducing the activation of the protein tyrosine
kinase focal adhesion kinase, which plays a prominent role in
integrin-mediated cellular adhesion (Polgárová et al., 2011).
6. Long-lasting tissue-protective effects of pHBSP: from animal
studies to clinical trials
6.1. Preclinical studies
In spite of a short half-life, in many systems pHBSP acts in a digital
(all-in-one) manner producing prolonged biological effects. The
beneﬁcial cardiovascular effects of acute administration of pHBSPwere demonstrated for the ﬁrst time in two rodent models of renal
I/R and middle cerebral artery occlusion injury, reporting degrees
of protection similar to those recorded when EPO was administered
(Brines et al., 2008). In the same study, protective capacities of
prolonged pHBSP administration (s.c. daily for 10 days) in the
healing of punch biopsy wounds have been provided. More recently,
we demonstrated that a delayed administration (as late as 6 h into
the reperfusion period) of a single dose of pHBSP was still able to
improve the functional recovery of the kidney after the onset of
reperfusion (after renal ischemia) in the rat (Patel et al., 2012). Similarly,
vanRijt and colleagues have reported that the beneﬁcial effects of pHBSP
(when administered by an intravenous injection at 0, 2, 4 and 6 h post-
reperfusion) in a porcinemodel of renal I/R were associated with signif-
icant reductions of biomarkers of acute inﬂammation (interleukin-6,
and monocyte chemotactic protein-1). The protection afforded by
pHBSP was still detectable at seven days post-reperfusion, and animals
treated with the peptide showed both improvements in glomerular
ﬁltration rate and reductions in interstitial ﬁbrosis (van Rijt et al.,
2013). Similar protective effects were observed when HBSP or the
carbamylated derivative of EPO, both devoid of any erythropoietic
activity, were tested in rat and mouse models of renal I/R injury
(Chattong et al., 2013; Wu et al., 2013; Yang et al., 2013).
Beneﬁcial effects of pHBSP have also been reported in other models
of injury associated with ischemia and/or reperfusion, including limb
ischemia, MI and traumatic brain injury. In an in vitro model of
myotube ischemia, pHBSP pretreatment decreased apoptotic nuclear
fragmentation and cleaved caspase-3 expression in a multinucleated
skeletal muscle cell line maintained under hypoxic conditions for
8 h. This effect was associated with a signiﬁcant reduction in IL-6
release from the ischemic myotubes (Joshi et al., 2014). In a model
of MI in the rat, a single systemic application of pHBSP immediately
after coronary ligation reduced the infarct size to the same extent
as that of EPO (Ahmet et al., 2011). This effect was associated with
a signiﬁcant reduction of necrosis, apoptosis and inﬂammation mea-
sured 24 h after MI induction in the area at risk. In addition, long-term
treatment (for 10 months, two times per week) with pHBSP attenuated
cardiac remodeling and reduced mortality in a rat model of post-MI-
dilated cardiomyopathy (Ahmet et al., 2013). Notably, the hematocrit
did not change signiﬁcantly during the 10-month experiment and it
did not produce any signs of arterial blood pressure elevation, thus
conﬁrming the assertion that continuous administration of pHBSP does
not trigger the known undesirable erythropoietic or hemodynamic
effects of EPO. In addition, pHBSP has been reported to exert protective
effects against progression of coronary atherosclerotic lesions in a rabbit
model that develops spontaneous MI, in part by inhibiting endothelial
cell apoptosis (Ueba et al., 2013).
In a model of mild brain injury complicated by hypotension induced
by withdrawal of blood, pHBSP administration every 12 h for 3 days
showed protective effects, reducing contusion volume and improving
recovery of cerebral blood ﬂow in the injured brain following resuscita-
tion (Robertson et al., 2012).Most notably, evenwhen pHBSPwas given
as late as 30 to 60 min into the resuscitation period after 90 min of
severe hemorrhage, single bolus injections of the peptide attenuated
the renal dysfunction, liver injury, skeletal muscle injury and lung
inﬂammation associated with severe hemorrhagic shock (Patel et al.,
2011b). There are also convincing data on the neuroprotective effects
of pHBSP, as shown using the experimental models of autoimmune
encephalomyelitis and autoimmune neuritis, which mimic the human
multiple sclerosis and the Guillain–Barré Syndrome, respectively.
Therapeutic administration of pHBSP to rats reduced severity and short-
ened duration of the experimental autoimmune encephalomyelitis,
probably by inhibiting the expression of inﬂammatory cytokines in
the spinal cord, suppressing lymphocyte proliferation and altering T
helper cell differentiation (Chen et al., 2014). Similarly, pHBSP greatly
decreased the severity of the neurological symptoms and shortened
the recovery time and total duration of the experimental autoimmune
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inﬁltration in peripheral nerves and exerting direct cyto-protective
and anti-inﬂammatory effects on Schwann cells, which are critical for
the remyelination of the injured nerves (Liu et al., 2014). The neuropro-
tective activity of the EPO derivative in the peripheral nervous system
has also been examined in rat models of post-status epilepticus model
and neuropathic pain. Speciﬁcally, pHBSP mediated effects on hippo-
campal cell proliferation and neurogenesis, with signiﬁcant improve-
ment in epileptogenesis-associated cognitive deﬁcits (Seeger et al.,
2011). In addition, administration of pHBSP was effective in providing
long-term relief of nerve injury-induced mechanical allodynia in both
the spared nerve injury model, based on sciatic nerve surgical transec-
tion, and the neuritis model, which lacks gross nerve pathology
(Swartjes et al., 2011; Pulman et al., 2013). A suppression of the
neuro-inﬂammatory response, shown by reduction in microglia activa-
tion,was also involved in the protective effects of pHBSP against chronic
neuropatic pain (Swartjes et al., 2014). Similarly, a reduction of the
innate inﬂammatory response, mainly suppression of TNF-αmediated
signaling, signiﬁcantly contributed to pHBSP-induced prevention of
the conversion of partial- to full-thickness burn injuries, in a mouse
model of deep dermal burns (Bohr et al., 2013).
Very recently, the use of βcR knockout mice has enabled us and
others to conﬁrm that the activation of the heteromeric EPOR-βcR
complex is indeed essential for the reduction of both kidney and cardiac
dysfunction associated with sepsis, as well as in producing long-term
relief of neuropathic pain (Swartjes et al., 2011; Coldewey et al., 2013;
Khan et al., 2013).
There are some limited, but exciting, recent data that the beneﬁcial
effects of pHBSP may also be of beneﬁt in animal models of diabetes
mellitus and its complications. pHBSP is highly effective at preventing
clinically relevant lesions of diabetic retinopathy, when administered
for 1 month at 6 months after the induction of diabetes, dampening
microglia activation and associated pro-inﬂammatory cytokine
expression (McVicar et al., 2011). In amousemodel of diabetic autonomic
neuropathy, treatment with pHBSP for 7 weeks decreased neuritic
dystrophy, thus further conﬁrming its neuroprotective effects
(Schmidt et al., 2011). Very recently, we demonstrated that the chronic
administration of pHBSP protects against the metabolic abnormalities,
including insulin resistance, caused by a diet containing high concentra-
tions of both fat and sugar. These effects were associated with pHBSP-
induced modulation of signal transduction pathways involved in both
insulin signaling and inﬂammation in the murine skeletal muscle. For
instance, pHBSP counteracted the diet-induced alterations in the phos-
phorylation of IRS-1 protein as well as the activities of the downstream
key insulin signalingmolecules, Akt andGSK-3β, anAkt substrate, and it
prevented local and systemic overproduction of myokines, such as IL-6
and FGF-21 (Collino et al., 2014). We also recorded protective effects
against the mitochondrial dysfunction, which is a cardinal feature of
insulin resistance.
6.2. Clinical studies
The above encouraging pre-clinical data have stimulated the following
clinical trials. The ﬁrst ones were two proof-of-concept clinical trials in
patients with chronic neuropathic pain aimed to obtain indication
of efﬁcacy and safety of pHBSP in patients with either sarcoidosis
or type 1 or 2 diabetes, with a pain score of at least 5/10. In the ﬁrst
study (Niesters et al., 2013), patients were treated with intravenous
pHBSP injections (2 mg in 9 mL saline, given over 2 min). A total of
three injections were administered at 2-day intervals. The one-week
pHBSP treatment in patients with sarcoidosis was associated with a
reduction in pain scores of 40% with the effect lasting for the 3 days
following the end of treatment. Similarly, in diabetic patients the
treatment resulted in a reduction in pain scores of 30% until at least
day 8. The second trial was aimed to assess whether pHBSP produces
analgesia greater than placebo in sarcoidosis-related neuropathicpain (Heij et al., 2012). This double-blind, randomized, placebo-
controlled trial was performed with 22 sarcoidosis patients, of which
12 received a 4-week pHBSP treatment (2 mg IV with 3 injections/
week); the others received normal saline instead of pHBSP. The prelim-
inary data analysis revealed that pHBSP-treated patients had a signiﬁcant
greater decrease in neuropathic symptoms and a signiﬁcant improve-
ment in pain scores as determined from a quality of life questionnaire
during the 4-week treatment period. No safety issues or adverse effects
were noted by clinical or laboratory assessments (e.g., as expected no
changes in hemoglobin concentration occurred). In light of the ﬁndings
from the open-label studies, a double-blind, randomized, controlled
trial has been recently performed in patients with sarcoidosis with
moderate to severe neuropathic pain (the NERVARA trial). In contrast
to the two previous trials, a subcutaneous formulation of pHBSP has
been used in order to allow the patients to self-inject daily. This
double-blind, randomized, placebo-controlled phase II trial conﬁrmed
the observations made in the open-label study showing that pHBSP
(administered three times weekly for 4 weeks and 12 weeks of follow-
up period) was associated with a signiﬁcant improvement in neuro-
pathic pain and autonomic symptoms, with no effect on hemoglobin
concentrations (Dahan et al., 2013).
An extensive double-blind, randomized, controlled trial of the
effects of 28 days of treatment with pHBSP in type 2 diabetes-related
small-ﬁber neuropathy has recently been completed (Brines et al.,
2014). Neuropathic symptoms, as assessed by the PainDetect question-
naire, improved to a clinically signiﬁcant degree in the patients treated
with pHBSP. Additionally, patients that received pHBSP also exhibited
improved HbA1c and lipid proﬁles throughout the 56-day observation
period. These observations suggest that pHBSP may improve metabolic
control and reduce neuropathic symptoms in patients with type 2
diabetes. These ﬁndings are very important andwarrant further clinical
evaluation.
7. Conclusions
There is now good evidence that activation of the EPOR-βcR hetero-
dimer by pHBSP (or EPO itself or othermolecules that mimic the tissue-
protective effects of EPO)when reaching a critical minimum concentra-
tion (N1 nmole/L) ﬂips a molecular switch that activates long-lasting
survival pathways (e.g., PI3K/Akt, eNOS), resulting in inhibition of
inﬂammation, apoptosis, and activation of repair. These effects were
observed in animal models of acute illness (e.g. MI, acute kidney injury,
stroke, hemorrhagic shock) in which the peptide was administered
after the injury, namely when up-regulation of the IRR has occurred.
These effects were also observed in patients with chronic disease
(diabetes mellitus or sarcoidosis) when the peptide was given repeti-
tively (therapeutic administration). These preclinical and early clinical
data provide a very good indication that the reported pharmacodynam-
ic effects of pHSBP may last signiﬁcantly longer than anticipated by its
pharmacokinetic half-life. This enables therapeutic intervention via a
pulse dosing protocol, which provides adequate receptor triggering
while limiting the potential side effects and improving patient compli-
ance. Most notably, the well-documented adverse effects of a chronic
administration of EPO (e.g. thrombovascular events) have not been
reported for pHSBP, making this molecule an ideal candidate to explore
the reported tissue-protective and anti-inﬂammatory effects of the acti-
vation of the IRR in chronic diseases, includingdiabetes and neuropathy.
Further phase 2 clinical trials evaluating the potential beneﬁcial and
adverse effects of pHSBP in chronic diseases are warranted, and their
results are expected with great anticipation.
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